Managing Nonadvanced Systemic Mastocytosis

Target Audience

The design of this activity addresses the needs of clinical immunologists, allergists, and dermatologists who manage patients with nonadvanced systemic mastocytosis (SM).

Program Overview

Nonadvanced systemic mastocytosis (SM) is a difficult disorder to diagnose and manage due to the wide variety of symptoms, anaphylactic triggers, and a complicated individualized treatment paradigm. This engaging Expert Roundtable™ program provides multidisciplinary insights related to the diagnosis and treatment strategies for nonadvanced SM.

Learning Objectives

After completing this activity, the participant should be better able to:

• Describe the pathophysiology of nonadvanced SM, including the effects of driver mutations on MC activation and the rationale for new targeted therapies
• Assess symptoms and analyze laboratory and genetic testing results to differentially diagnose nonadvanced SM and classify subtype
• Discuss recent clinical trial evidence and regulatory status for new and emerging targeted treatment options, including selective tyrosine kinase inhibitors and their role in treating SM
• Formulate individualized treatment plans reflecting clinical evidence for treatment efficacy and safety, patient-reported outcomes, and shared decision making

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Continuing Medical Education

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pretest, posttest, and program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

John M. Fahrenholz, MD: Consulting Fees: Blueprint Medicines Corporation, Cogent Biosciences; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Blueprint Medicines Corporation; Contracted Research: Cogent Biosciences

Lauren M. Madigan, MD: Consulting Fees: Blueprint Medicines Corporation; Other: JAMA Dermatology (co-section editor)

Anton Rets, MD: Consulting Fees: Blueprint Medicines Corporation

The Integritas planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.